Blog
Valuable TargetsAdvanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
BI-1815368 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
BI-1815368 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
BI-1815368: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Tobramycin sulfate /Vancomycin Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Tobramycin sulfate /Vancomycin Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Tobramycin sulfate /Vancomycin Hydrochloride: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
LYCovMab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
LYCovMab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
LYCovMab: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Thiostrepton Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Thiostrepton Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Thiostrepton: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Blixeprodil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Blixeprodil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Blixeprodil: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
[18F]-AzaFol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
[18F]-AzaFol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
[18F]-AzaFol: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Elifactant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Elifactant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Elifactant: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Enistimagene Setitucel/Damistimagene Matitucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Enistimagene Setitucel/Damistimagene Matitucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Enistimagene Setitucel/Damistimagene Matitucel: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Imarikiren hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Imarikiren hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Imarikiren hydrochloride: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Danusertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Danusertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Danusertib: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Read →
EXOC3L1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
EXOC3L1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for EXOC3L1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
EXOC3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
EXOC3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for EXOC3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →